Pune: The Serum Institute of India (SIII) has said it will seek permission from the Drug Controller and General of India (DCGI) to test children in the country for the Kovid vaccine, a Kovid vaccine from US company Novavax. The third phase of Kovovax trials began on June 18. This is the second Kovid vaccine to be manufactured at Pune-based SII.
‘The new milestone has arrived. This week we produced the first batch of Kovovax in Pune. The vaccine has a great potential to protect our future generations under the age of 18. Experiments for this are continuing, ”tweeted SII CEO Adar Poonawale. Initially, the company was trying to conduct clinical trials of Kovovax for 12-18 year olds and later for 12 year olds, The New Indian Express reported.
The Serum Institute also manufactures and distributes the Covshield vaccine, which was developed in collaboration with AstraZeneca and Oxford University. Poonawale had earlier said that it expects Kovacs to be available by September this year. In September 2020, Novavox and SII announced a manufacturing contract for the production of the NVX-Cove 2373 vaccine.
English Summary: Serum to Seek DCGI Nod for Covovax Trial on Children, CEO Bats for its ‘Great Potential’ to Save Next Gen